
Morepen Labs' Facility Clears USFDA Inspection with NIL Adverse Observation for the Record Fourth Consecutive Time
Morepen Laboratories Limited (NSE: MOREPENLAB; BSE: 500288) has announced the successful completion of a USFDA (United States Food and Drug Administration) inspection at its Masulakhanna (Himachal) facility, with Zero adverse observations (No Form 483 issued by the drug regulator). This



